Galena Biopharma, Inc. (Galena) is a biopharmaceutical company. The Company is focused on developing and commercializing oncology therapeutics that address medical needs across a spectrum of cancer care. Galena’s development portfolio ranges from mid- to late-stage clinical assets, including an immunotherapy program led by NeuVax (nelipepimut-S) currently in an international, Phase 3 clinical trial. The Company’s commercial drugs include Abstral (fentanyl) Sublingual Tablets and Zuplenz (ondansetron) Oral Soluble Film. It also offers peptide immunotherapy product candidate, GALE-301 (Folate Binding Protein), an immunogenic peptide combined with rhGM-CSF that can stimulate cytotoxic T lymphocyte (CTLs) to recognize and destroy Folate Binding Protein (FBP) expressing cancer cells.